Mukul Agrawal-Backed Small-Cap Specialty Chemicals Stock Jumps 17% After Reporting Strong Q1 FY27 Results; PAT Surges 962% YoY

On Thursday, Indian equity benchmark indices traded marginally higher, with the benchmark Nifty 50 index rising 10.20 points, or 0.04 per cent, to 24,634.85. Amid the broader market gains, Neuland Laboratories share price jumped 10 per cent to Rs 21950 after the company reported a strong set of financial results for the quarter ended June 30, 2026.

Neuland Laboratories Q1 FY27 Financial Performance

Neuland Laboratories reported a strong financial performance for the quarter ended June 30, 2026. The company reported revenue from operations of Rs 641.58 crore in Q1 FY27, compared with Rs 292.75 crore in the corresponding quarter last year, registering a 119.2 per cent YoY growth. On a sequential basis, revenue declined 17.3 per cent from Rs 776.25 crore reported in Q4 FY26.
Total income stood at Rs 650.07 crore, up 116.3 per cent YoY from Rs 300.61 crore, while declining 17.6 per cent QoQ from Rs 788.71 crore.

Profit before Tax (PBT) increased to Rs 197.85 crore in Q1 FY27 from Rs 17.57 crore in the year-ago quarter, registering a 1,025.8 per cent YoY growth. On a quarter-on-quarter basis, PBT declined 31.2 per cent from Rs 287.49 crore in Q4 FY26. Profit after tax (PAT) surged to Rs 147.67 crore, compared with Rs 13.90 crore in Q1 FY26, reflecting a 962.4 per cent YoY growth. Sequentially, PAT declined 30.6 per cent from Rs 212.67 crore reported in the previous quarter.

Strategic Collaboration with Gland Pharma

The Board approved the execution of an irrevocable corporate guarantee of Rs 40 crore in favour of Gland Pharma Limited in connection with a proposed Loan Licence Agreement. Under the agreement, Gland Pharma will establish dedicated manufacturing capacity and incur capital expenditure for manufacturing certain sterile API products. The company stated that the guarantee represents a contingent liability and has no immediate financial impact.
Also Read - Savita Oil Technologies Share Price Jumps 17%; Here’s Why

Separately, the two companies announced a long-term strategic CDMO partnership to manufacture sterile Active Pharmaceutical Ingredients (APIs). As part of the collaboration, Gland Pharma will establish a dedicated sterile manufacturing suite at its Visakhapatnam facility, adding around 1,400 kg of annual manufacturing capacity. The partnership aims to combine Neuland's expertise in complex APIs with Gland Pharma's sterile manufacturing capabilities to serve growing global demand for injectable therapies.

Manufacturing Capacity Expansion

The Board also approved an expansion of manufacturing capacity at Unit-1 in Bonthapally, Telangana. The project involves adding 18 KL of capacity to the existing 376.5 KL facility, which is currently operating at 91 per cent utilisation. The expansion, to be completed within six to seven months, will require an investment of Rs 39.8 crore, funded entirely through internal accruals, to cater to rising customer demand.

Neuland Laboratories Shareholding Pattern

The company's shareholding pattern for the June 2026 quarter reflected increased institutional participation. Foreign Institutional Investors (FIIs) raised their stake to 21.08 per cent from 20.46 per cent in the March 2026 quarter, while Domestic Institutional Investors (DIIs) increased their holding to 16.52 per cent from 15.84 per cent.

Among notable public shareholders, Ace Investor Mukul Mahavir Agrawal continued to hold a 3.12 per cent stake in the company during the June 2026 quarter. Kedia Securities Private Limited also maintained its 1.01 per cent stake, while Siddharth Iyer held 1.67 per cent of the company's equity, reflecting continued participation from well-known market investors.

What are your views on Neuland Laboratories' strong Q1 FY27 performance? Share your thoughts in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.